CLSD
Income statement / Annual
Last year (2023), Clearside Biomedical, Inc.'s total revenue was $8.23 M,
an increase of 519.89% from the previous year.
In 2023, Clearside Biomedical, Inc.'s net income was -$32.49 M.
See Clearside Biomedical, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$8.23 M
|
$1.33 M
|
$29.58 M
|
$7.89 M
|
$2.17 M
|
$30,000.00
|
$345,000.00
|
$520,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$355,000.00 |
$204,000.00 |
$178,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$33,000.00 |
$0.00 |
| Gross Profit |
$7.87 M |
$1.12 M |
$29.40 M |
$7.89 M |
$2.17 M |
$30,000.00 |
$345,000.00 |
$520,000.00 |
-$33,000.00 |
$0.00 |
| Gross Profit Ratio |
0.96 |
0.85 |
0.99 |
1 |
1 |
1 |
1 |
1 |
0 |
0 |
| Research and Development
Expenses |
$20.85 M
|
$19.63 M
|
$18.54 M
|
$15.07 M
|
$15.66 M
|
$68.29 M
|
$49.05 M
|
$19.46 M
|
$10.76 M
|
$6.69 M
|
| General & Administrative
Expenses |
$11.87 M
|
$11.77 M
|
$11.67 M
|
$10.76 M
|
$16.82 M
|
$14.68 M
|
$9.70 M
|
$6.26 M
|
$6.56 M
|
$3.13 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.87 M
|
$11.77 M
|
$11.67 M
|
$10.76 M
|
$16.82 M
|
$14.68 M
|
$9.70 M
|
$6.26 M
|
$6.56 M
|
$3.13 M
|
| Other Expenses |
$0.00 |
$669,000.00 |
$1.00 M |
-$275,000.00 |
-$466,000.00 |
$127,000.00 |
-$567,000.00 |
-$684,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$32.72 M |
$31.40 M |
$30.20 M |
$25.83 M |
$32.48 M |
$82.98 M |
$58.75 M |
$25.72 M |
$17.32 M |
$9.82 M |
| Cost And Expenses |
$33.07 M |
$31.60 M |
$30.20 M |
$25.83 M |
$32.48 M |
$82.98 M |
$58.75 M |
$25.72 M |
$17.32 M |
$9.82 M |
| Interest Income |
$0.00 |
$669,000.00 |
$0.00 |
$335,000.00 |
$1.03 M |
$0.00 |
$0.00 |
$0.00 |
$8,000.00 |
$5,000.00 |
| Interest Expense |
$9.36 M |
$3.34 M |
$0.00 |
$335,000.00 |
$1.03 M |
$0.00 |
$0.00 |
$0.00 |
$330,000.00 |
$371,000.00 |
| Depreciation &
Amortization |
$67,000.00
|
$145,000.00
|
$178,000.00
|
$180,000.00
|
$211,000.00
|
$189,000.00
|
$182,000.00
|
$65,000.00
|
$60,000.00
|
$33,000.00
|
| EBITDA |
-$23.06 M
|
-$29.46 M
|
-$449,000.00
|
-$17.94 M
|
-$30.09 M
|
-$82.76 M
|
-$58.23 M
|
-$25.13 M
|
-$17.26 M
|
-$9.79 M
|
| EBITDA Ratio |
-2.8 |
-22.31 |
-0.02 |
-2.27 |
-13.95 |
-2764.83 |
-169.3 |
-48.46 |
0 |
0 |
| Operating Income Ratio
|
-3.02
|
-22.82
|
-0.02
|
-2.27
|
-13.95
|
-2764.83
|
-169.3
|
-48.46
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$7.64 M
|
-$2.67 M
|
$1.00 M
|
-$275,000.00
|
-$466,000.00
|
$127,000.00
|
-$567,000.00
|
-$684,000.00
|
-$322,000.00
|
-$366,000.00
|
| Income Before Tax |
-$32.49 M |
-$32.95 M |
$376,000.00 |
-$18.21 M |
-$30.77 M |
-$82.82 M |
-$58.98 M |
-$25.88 M |
-$17.64 M |
-$10.19 M |
| Income Before Tax Ratio
|
-3.95
|
-24.83
|
0.01
|
-2.31
|
-14.16
|
-2760.6
|
-170.94
|
-49.77
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$1.12 M |
-$58,558.00 |
-$180,000.00 |
-$211,000.00 |
$127,000.00 |
-$182,000.00 |
-$65,000.00 |
$8,000.00 |
$5,000.00 |
| Net Income |
-$32.49 M |
-$34.07 M |
$376,000.00 |
-$18.03 M |
-$30.56 M |
-$82.82 M |
-$58.98 M |
-$25.88 M |
-$17.64 M |
-$10.19 M |
| Net Income Ratio |
-3.95 |
-25.68 |
0.01 |
-2.28 |
-14.06 |
-2760.6 |
-170.94 |
-49.77 |
0 |
0 |
| EPS |
-0.53 |
-0.57 |
0.0064 |
-0.39 |
-0.8 |
-2.69 |
-2.33 |
-1.97 |
-1.44 |
-0.83 |
| EPS Diluted |
-0.53 |
-0.57 |
0.0063 |
-0.39 |
-0.8 |
-2.69 |
-2.33 |
-1.97 |
-1.44 |
-0.83 |
| Weighted Average Shares
Out |
$61.81 M
|
$60.20 M
|
$58.49 M
|
$46.51 M
|
$38.17 M
|
$30.73 M
|
$25.31 M
|
$13.11 M
|
$12.27 M
|
$12.27 M
|
| Weighted Average Shares
Out Diluted |
$61.81 M
|
$60.20 M
|
$59.91 M
|
$46.51 M
|
$38.17 M
|
$30.73 M
|
$25.31 M
|
$13.11 M
|
$12.27 M
|
$12.27 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
